We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Read MoreHide Full Article
Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) announced data from a new post hoc analysis of its phase III inTandem3 study that evaluated sotagliflozin for the treatment of patients with type 1 diabetes and chronic kidney disease (CKD).
Data from the new post hoc analysis showed that treatment with sotagliflozin improved glycemic control in the given patient population, while also successfully lowering A1C (blood sugar levels), body weight and systolic blood pressure.
Per the press release, in a subgroup of patients with type 1 diabetes and CKD, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts, relative to placebo. Treatment with sotagliflozin was also associated with the same risks of severe hypoglycemia between the two cohorts.
This might have hurt investors’ sentiments and resulted in the stock to go down 10.3% on Mar 12, following the announcement of the news.
The company is currently preparing to resubmit the new drug application seeking approval for sotagliflozin as an adjunct to insulin therapy in people with type 1 diabetes and CKD.
Shares of Lexicon have rallied 9.1% in the past year against the industry’s decline of 5.8%.
Image Source: Zacks Investment Research
We remind investors that FDA approved sotagliflozin under the brand name of Inpefa to reduce the risk of death and hospitalization in adults with either heart failure or those with type II diabetes mellitus, CKD and other cardiovascular risk factors in May 2023.
An oral SGLT inhibitor, the commercial launch of Inpefa continues to progress in the United States. The drug is witnessing increasing demand across the cardiology community and improving payer access.
Meanwhile, Inpefa was placed as a preferred product on pharmacy benefits manager Express Scripts’ Medicare national formularies effective Nov 1, 2023.
Express Scripts placed Inpefa on its Premier Access and Premier Performance national formularies for Medicare patients. As a result of this placement, Express Scripts’ Medicare patients in specific plans will now be able to access Inpefa, thereby expanding the drug’s market reach.
Lexicon is also planning to develop Inpefa in a phase III study for treating hypertrophic cardiomyopathy.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 18 cents to 30 cents. In the past year, ADMA shares have risen 92%.
ADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.
In the past 60 days, the Zacks Consensus Estimate for Vanda Pharmaceuticals’ 2024 bottom line has improved from a loss of 46 cents per share to earnings of 1 cent. In the past year, VNDA shares have plunged 36.4%.
VNDA’s earnings beat estimates in each of the trailing three quarters, the average surprise being 92.88%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.40. In the past year, ANIP shares have gained 62.4%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.60%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) announced data from a new post hoc analysis of its phase III inTandem3 study that evaluated sotagliflozin for the treatment of patients with type 1 diabetes and chronic kidney disease (CKD).
Data from the new post hoc analysis showed that treatment with sotagliflozin improved glycemic control in the given patient population, while also successfully lowering A1C (blood sugar levels), body weight and systolic blood pressure.
Per the press release, in a subgroup of patients with type 1 diabetes and CKD, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts, relative to placebo. Treatment with sotagliflozin was also associated with the same risks of severe hypoglycemia between the two cohorts.
This might have hurt investors’ sentiments and resulted in the stock to go down 10.3% on Mar 12, following the announcement of the news.
The company is currently preparing to resubmit the new drug application seeking approval for sotagliflozin as an adjunct to insulin therapy in people with type 1 diabetes and CKD.
Shares of Lexicon have rallied 9.1% in the past year against the industry’s decline of 5.8%.
Image Source: Zacks Investment Research
We remind investors that FDA approved sotagliflozin under the brand name of Inpefa to reduce the risk of death and hospitalization in adults with either heart failure or those with type II diabetes mellitus, CKD and other cardiovascular risk factors in May 2023.
An oral SGLT inhibitor, the commercial launch of Inpefa continues to progress in the United States. The drug is witnessing increasing demand across the cardiology community and improving payer access.
Meanwhile, Inpefa was placed as a preferred product on pharmacy benefits manager Express Scripts’ Medicare national formularies effective Nov 1, 2023.
Express Scripts placed Inpefa on its Premier Access and Premier Performance national formularies for Medicare patients. As a result of this placement, Express Scripts’ Medicare patients in specific plans will now be able to access Inpefa, thereby expanding the drug’s market reach.
Lexicon is also planning to develop Inpefa in a phase III study for treating hypertrophic cardiomyopathy.
Zacks Rank & Stocks to Consider
Lexicon currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the healthcare sector are ADMA Biologics, Inc. (ADMA - Free Report) , Vanda Pharmaceuticals Inc. (VNDA - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 18 cents to 30 cents. In the past year, ADMA shares have risen 92%.
ADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.
In the past 60 days, the Zacks Consensus Estimate for Vanda Pharmaceuticals’ 2024 bottom line has improved from a loss of 46 cents per share to earnings of 1 cent. In the past year, VNDA shares have plunged 36.4%.
VNDA’s earnings beat estimates in each of the trailing three quarters, the average surprise being 92.88%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.40. In the past year, ANIP shares have gained 62.4%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.60%.